Johnson&Johnson CEO: Currently has no intention of producing weight loss drugs and focuses on expanding into fields such as neurology and oncology
我放心你带套猛
发表于 2023-12-6 09:51:55
284
0
0
Johnson&Johnson CEO Joaquin Duato stated at the company's Investor Day event on December 5th that the company currently has no plans to produce weight loss pills due to the intense competition in the market.
Du Anqing stated that Johnson&Johnson is focusing on expanding widely in fields such as neurology and oncology. Du Anqing said, "If Johnson&Johnson has the opportunity to stand out in the weight loss drug market through assets that complement the company's business, it may reconsider."
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- Is Johnson&Johnson clearing Kenvue shares and withdrawing from the skincare and beauty industry a win-win situation or a last resort?
- Qiangsheng subsidiary responds to "shortage of focus in Daduo": the company faces supply pressure and challenges due to a significant increase in market demand
- Lilly: We have applied to the FDA for the weight loss drug Zepbound to treat sleep apnea, and it is expected to be approved as early as the end of the year
- Johnson&Johnson appoints Zhou Mintao as President of Medical Technology China
- Johnson&Johnson China completes business changes, with Song Weiqun stepping down as chairman
- Johnson&Johnson China CEO Song Weiqun steps down as Chairman of Johnson&Johnson China
- Novo Nordisk reaches settlement with Mylan Pharmaceuticals over patent dispute over weight loss drug Ozempic and Wegovy
- Citigroup raises Johnson&Johnson's target price from $180 to $185
- Johnson&Johnson China's multiple product lines have been exposed to layoffs! An employee reported a layoff scale of 20%
- Eli Lilly and Sinopharm deepen cooperation in the field of oncology
